Drug
Rucaparib clinical trials
Also written Rubraca, CO-338 and PF 01367338.
- studies test it
- 54
- open now
- 2
- in phase 3
- 6
- first study started
- 2007
Keep track of what changes. Save the rucaparib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
54 studies that test it; most in 2019 (14)
| Year | Studies |
|---|---|
| 2007 | 2 |
| 2010 | 2 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 6 |
| 2017 | 6 |
| 2018 | 12 |
| 2019 | 14 |
| 2020 | 5 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 17
- Phase 2
- 37
- Phase 3
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 24 · Other 30
pharmaand GmbH (18) · Bristol-Myers Squibb (3) · Memorial Sloan Kettering Cancer Center (2) · University of Michigan Rogel Cancer Center (2) · Hoffmann-La Roche (2) · Dana-Farber Cancer Institute (1) · Royal Marsden NHS Foundation Trust (1) · Brown University (1)
Often tested with
Tested in the same studies.
Nivolumab (9) · Bevacizumab (5) · Pembrolizumab (4) · Atezolizumab (4) · Capecitabine (2) · Durvalumab (2) · Fluorouracil (2) · Leucovorin (2)
Studies
Open first, then newest update. How each study uses rucaparib is read from its arms, and is right about nine times in ten.
Testing it · 54
- Pan Tumor Rollover StudyRecruitingPhase 2Bristol-Myers SquibbNCT03899155Written as Rucaparib
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234Written as Rucaparib
- PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell CancersCompletedPhase 1/2National Cancer Institute (NCI)NCT04209595Written as Rucaparib
- Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair DeficiencyTerminatedPhase 2University of WashingtonNCT03442556Written as Rucaparib Camsylate
- Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant MesotheliomaCompletedPhase 2University of LeicesterNCT03654833Written as Rucaparib
- A Study of Rucaparib and Nivolumab in People With LeiomyosarcomaActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT04624178Written as Rucaparib
- The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)CompletedPhase 2Medical College of WisconsinNCT03694262Written as Rucaparib
- A Phase II Study Of Nivolumab/ Bevacizumab/RucaparibActive, not recruitingPhase 2Dana-Farber Cancer InstituteNCT02873962Written as Rucaparib
- Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial CancerCompletedPhase 2University of Colorado, DenverNCT03617679Written as Rucaparib
- Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung CancerTerminatedPhase 1/2University of Michigan Rogel Cancer CenterNCT03559049Written as Rucaparib
- An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate CancerCompletedPhase 2Bristol-Myers SquibbNCT03338790Written as rucaparib
- A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following ChemotherapyCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT03542175Written as Rucaparib
- Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid TumorsTerminatedPhase 2Gustave Roussy, Cancer Campus, Grand ParisNCT04276376Written as Rucaparib
- A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene DeficiencyCompletedPhase 3pharmaand GmbHNCT02975934Written as Rucaparib
- A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based ChemotherapyActive, not recruitingPhase 3pharmaand GmbHNCT03522246Written as Rucaparib
- Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy TrialActive, not recruitingPhase 2Royal Marsden NHS Foundation TrustNCT02678182Written as Rucaparib
- Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum TherapyCompletedPhase 2University of Michigan Rogel Cancer CenterNCT03639935Written as Rucaparib
- Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)CompletedPhase 2SWOG Cancer Research NetworkNCT03845296Written as Rucaparib
- A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate CancerActive, not recruitingPhase 1/2Brown UniversityNCT04253262Written as Rucaparib
- Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants with Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal CancerCompletedPhase 1Ohio State University Comprehensive Cancer CenterNCT03552471Written as Rucaparib Camsylate
See all 54 studies that test rucaparib →
Given in every arm · 8 — rucaparib is usual care beside what is tested
- A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab StudyActive, not recruitingPhase 3Hoffmann-La RocheNCT03768063Written as Rucaparib
- A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation TherapyActive, not recruitingPhase 3Alliance for Clinical Trials in OncologyNCT04455750Written as Rucaparib camsylate
- Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesTerminatedPhase 1/2Incyte CorporationNCT02711137Written as Rucaparib
- Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 MonthsTerminatedPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT04826198Written as Rucaparib
- A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)TerminatedPhase 1/2pharmaand GmbHNCT03992131Written as Rucaparib
- Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)CompletedPhase 1pharmaand GmbHNCT04179396Written as Rucaparib
- Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal AdenocarcinomaStatus unknownPhase 1/2University of Kansas Medical CenterNCT03995017Written as Rucaparib
- Rucaparib and Irinotecan in Cancers With Mutations in DNA RepairCompletedPhase 1Pamela MunsterNCT03318445Written as Rucaparib
Codes
What other systems call rucaparib · ClinicalTrials.gg INT005325
- MeSH (NLM) C531549rucaparibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 8237F3U7EHRUCAPARIBConfirmed FDA, NLM, Wikidata
- RxNorm 1862579Confirmed FDA, Wikidata
- Wikidata Q7376558rucaparibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C137800RucaparibConfirmed FDA, Wikidata
- DrugBank DB12332One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C531549 | rucaparib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 8237F3U7EH | RUCAPARIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1862579 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7376558 | rucaparib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C137800 | Rucaparib | Confirmed FDA, Wikidata |
| DrugBank | DB12332 | — | One source Wikidata |
Also registered as rucaparib camsylate (UNII 41AX9SJ8KO · RxNorm 1862578) and rucaparib phosphate (UNII H3M9955244).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.